These results further supported the likelihood that suppression of oxidative stress response by inhibiting the FAK/YAP/TRX pathway and ROS1 inhibition was indeed responsible for the anti-tumor effects of the combination treatment. This evidence concerns the gene PTK2 and neoplasm.